Literature DB >> 19828940

Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats.

Alan Gill1, Kathleen Wortham, Don Costa, Wendell Davis, Barry Ticho, Eric Whalley.   

Abstract

BACKGROUND/AIMS: Cisplatin (CIS) induces nephrotoxicity partly through renal vasoconstriction and decreased glomerular filtration effects thought to involve adenosine acting on adenosine A(1) receptors (A1Rs). We studied the effect of the orally active, A1R antagonist tonapofylline (BG9928) on biochemical measures of renal function in CIS-induced acute kidney injury (AKI) in rats.
METHODS: Tonapofylline, 1 mg/kg b.i.d., p.o., was administered on days 0-1 or 0-6 to rats treated with CIS 5.5 mg/kg i.v. Prednisolone (PRED) 5 mg/kg s.c. (day 0) served as a positive control. Serum creatinine and urea nitrogen (BUN) were measured in serial blood samples taken over the 13-day study period.
RESULTS: CIS produced significant elevations in creatinine, reduction in body weight and marked proximal tubular injury throughout the renal cortex and outer medulla. Tonapofylline, days 0-1 or 0-6 and PRED all produced sustained reductions in post-CIS serum creatinine and BUN levels compared with controls, improved body weight recovery and significant attenuation of CIS-induced kidney pathology scores.
CONCLUSION: These data support the involvement of A1Rs in CIS-induced AKI in rats. Tonapofylline may be useful in the clinical setting for the prevention of kidney failure induced by nephrotoxic agents such as CIS. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828940     DOI: 10.1159/000248762

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  8 in total

Review 1.  Purinergic signalling in the kidney in health and disease.

Authors:  Geoffrey Burnstock; Louise C Evans; Matthew A Bailey
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

Review 2.  The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.

Authors:  Veena Roberts; Bo Lu; Siddharth Rajakumar; Peter J Cowan; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2012-11-29       Impact factor: 3.765

3.  HMGB1-TLR4 signaling participates in renal ischemia reperfusion injury and could be attenuated by dexamethasone-mediated inhibition of the ERK/NF-κB pathway.

Authors:  Jiong Zhang; Jumei Xia; Ying Zhang; Fang Xiao; Jin Wang; Hongyu Gao; Yanyan Liu; Song Rong; Ying Yao; Gang Xu; Junhua Li
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 4.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

5.  Adenosine A1 receptor antagonist, L-97-1, improves survival and protects the kidney in a rat model of cecal ligation and puncture induced sepsis.

Authors:  Constance N Wilson; Constance O Vance; Melissa G Lechner; George M Matuschak; Andrew J Lechner
Journal:  Eur J Pharmacol       Date:  2014-07-18       Impact factor: 4.432

Review 6.  Targeting of adenosine receptors in ischemia-reperfusion injury.

Authors:  Victor E Laubach; Brent A French; Mark D Okusa
Journal:  Expert Opin Ther Targets       Date:  2010-11-29       Impact factor: 6.902

7.  Adenosine receptor agonist NECA increases cerebral extravasation of fluorescein and low molecular weight dextran independent of blood-brain barrier modulation.

Authors:  Chih-Chung Cheng; Ya Lan Yang; Kate Hsiurong Liao; Ted Weita Lai
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

8.  Impact of Steroids on the Inflammatory Response after Ischemic Acute Kidney Injury in Rats.

Authors:  J Fontana; A Vogt; A Hohenstein; U Vettermann; E Doroshenko; E Lammer; B A Yard; S Hoeger
Journal:  Indian J Nephrol       Date:  2017 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.